# To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet

> **NCT01764178** · PHASE1 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 52 (actual)

## Conditions studied

- Hyperlipidemia
- Hypertension

## Interventions

- **DRUG:** Livalo fixed combination drug
- **DRUG:** Pitavastatin, Valsartan

## Key facts

- **NCT ID:** NCT01764178
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-22
- **Primary completion:** 2013-03-15
- **Final completion:** 2013-12-27
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01764178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01764178, "To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01764178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*